Represents the additional milestone payments to be made under the license agreement.

No definition available.

Name:	incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of deliverables under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementNumberOfDeliverables
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of future global development costs funded under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of the upfront payment made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of associated royalty payments from the initiation of a Phase IIb trial provided the entity elects not to co-develop any compounds and/or indications.

+ References

No definition available.

+ Details

Name:	incy_PercentageRoyaltyPaymentsOnElectionOfNotCodevelopmentOfCompounds
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty payment receivable under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_RoyaltyPaymentReceivable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 32
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_MilestoneRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_EliLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_GvhdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License agreements - Lilly (Details) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended				106 Months Ended
License agreements - Lilly (Details) $ in Thousands	Mar. 31, 2016 USD ($)	Jul. 31, 2010	Dec. 31, 2009 USD ($) item	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2010 USD ($)	Sep. 30, 2018 USD ($)
License agreements
Research and Development Expense				$ 292,527	$ 269,557	$ 893,719	$ 879,263
Revenues				449,700		1,353,500
Milestone revenues
License agreements
Revenues				20,000		120,000
Product royalty revenues
License agreements
Revenues				61,900		165,600
Eli Lilly
License agreements
Upfront payment received under license agreement			$ 90,000
Research and Development Expense				18,900	9,100	45,600	27,200
Number of deliverables under license agreement \| item			2
Product royalties in accounts receivable				$ 11,100		$ 11,100		$ 4,600				$ 11,100
Eli Lilly \| Maximum
License agreements
Associated future royalty payments from the initiation of a Phase IIb trial, if elected to not co-develop, percentage						20.00%
Eli Lilly \| Phase IIB
License agreements
Funding of future development costs (as a percent)		30.00%		30.00%		30.00%
Eli Lilly \| Pre-specified Events \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 665,000
Eli Lilly \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone						$ 20,000		30,000				149,000
Eli Lilly \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			150,000
Eli Lilly \| Development Milestones \| Phase III
License agreements
Amount recognized and received for the achievement of a predefined milestone										$ 50,000
Eli Lilly \| Development Milestones \| Phase IIA
License agreements
Amount recognized and received for the achievement of a predefined milestone											$ 30,000
Eli Lilly \| Development Milestones \| Phase IIB
License agreements
Amount recognized and received for the achievement of a predefined milestone											$ 19,000
Eli Lilly \| Regulatory Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone						100,000						$ 235,000
Eli Lilly \| Regulatory Milestones \| JAPAN
License agreements
Amount recognized and received for the achievement of a predefined milestone								15,000
Eli Lilly \| Regulatory Milestones \| U.S.
License agreements
Amount recognized and received for the achievement of a predefined milestone									$ 35,000
Eli Lilly \| Regulatory Milestones \| Europe
License agreements
Amount recognized and received for the achievement of a predefined milestone								$ 65,000	$ 20,000
Eli Lilly \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			365,000
Eli Lilly \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 150,000
Eli Lilly \| GVHD
License agreements
Upfront payment under license agreement	$ 35,000
Additional milestone payments under the license agreement	$ 40,000
Eli Lilly \| Milestone revenues
License agreements
Revenues				$ 20,000	15,000	120,000	80,000
Eli Lilly \| Product royalty revenues
License agreements
Revenues				$ 11,000	$ 3,200	$ 26,200	$ 4,500